Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

Wednesday, May 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals has announced the acceptance of a peer-reviewed manuscript detailing the preclinical findings of its drug candidate SKNY-1. The study highlights significant results, including weight loss, lipid normalization, and a decrease in compulsive feeding and nicotine-seeking behaviors. This publication is expected to bolster the company's position in the market.
Price reaction · baseline $1.02 (2026-05-12 close) · hit pre-market · 1 other MIRA headline(s) in the window, move may be shared
day 0 close · peak
-4.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Peer-reviewed publication accepted, enhancing credibility.
  • Demonstrated weight loss and lipid normalization in preclinical findings.
  • Reduction in compulsive feeding and nicotine-seeking behaviors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+5%
120-day peak, hindsight
Typical move
0.6%
average across 2 past catalysts
Cash runway
~21 mo
Low dilution risk

Full Press Release Details

Peer-reviewed publication highlights preclinical findings demonstrating weight loss, lipid normalization, and reduction of compulsive feeding and nicotine-seeking behaviors MIAMI, FL / ACCESS Newswire / May 13, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”) , a clinical-stage pharmaceutical company focused on the development of investigational therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the acceptance and public…
You can read the full content here

Frequently Asked Questions

What is the focus of MIRA Pharmaceuticals?

MIRA Pharmaceuticals focuses on developing therapeutics for neurologic, neuropsychiatric, and metabolic disorders.

What findings were highlighted in the SKNY-1 manuscript?

The manuscript highlights weight loss, lipid normalization, and reduced compulsive feeding and nicotine-seeking behaviors.

What does peer-reviewed publication signify for MIRA?

Acceptance of the manuscript enhances MIRA's credibility and supports the efficacy of SKNY-1.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA Pharmaceuticals SKNY-1 obesity drug nicotine addiction peer-reviewed publication
Last updated: May 13, 2026

Biotech snapshot

Cash runway
$9M liquidity · $0M/mo burn
~21 mo
Low dilution risk

Catalyst track record

+5%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →